Lenskart Share Price 2026: Stock Hits All-Time High of ₹526 After Q3 Profit Surges 7,000%; Brokerages Raise Targets
MUMBAI – Lenskart Solutions Ltd., India’s largest omnichannel eyewear retailer, has stormed into the record books in February 2026. Riding on the back of a blockbuster Q3 FY26 earnings report, the stock soared over 13% in a single session, hitting a fresh all-time high of ₹526.35 on the BSE .
This marks the company’s highest share price since its November 2025 listing, with the stock now trading nearly 31% above its IPO issue price of ₹402. The rally has propelled Lenskart’s market capitalisation to approximately ₹88,000 crore (US$10.6 billion) , cementing its position as one of the most valuable new-age consumer companies in India .
📈 Lenskart Share Price 2026: Key Levels & Performance Snapshot
| Metric | Value |
|---|---|
| Current Share Price (Feb 11, 2026) | ₹526.35 (All-Time High) |
| Previous Close (Feb 10, 2026) | ₹466.35 |
| Intraday Gain | +12.86% to 13% |
| IPO Issue Price (Nov 2025) | ₹402 |
| Listing Price (Nov 2025) | ₹390 (3% discount) |
| 52-Week Low (Post-Listing) | ₹355.70 |
| Return Since Listing | +31% |
| 1-Month Return | +11% |
| YTD 2026 Return | +15% |
| Market Capitalisation | ~₹88,000 Cr (~$10.6 Bn) |
| P/E Ratio | ~253x |
| Face Value | ₹2 |
🚀 The Q3 Catalyst: Profit Jumps 7,000%, Revenue Up 38%
The sharp rally in Lenskart’s share price was triggered by the company’s December 2025 quarter results, announced on February 10, 2026. The numbers were nothing short of spectacular .
🔹 Consolidated Financial Highlights (Q3 FY26 vs Q3 FY25)
| Parameter | Q3 FY26 | Q3 FY25 | Change (YoY) | Change (QoQ) |
|---|---|---|---|---|
| Net Profit | ₹131 Cr | ₹1.85 Cr | +6,981% | +28% |
| Revenue from Operations | ₹2,307.7 Cr | ₹1,668.8 Cr | +38.3% | +10.9% |
| EBITDA | ₹464 Cr | ₹212 Cr | +118.9% | +11.8% |
| EBITDA Margin | 20.1% | 12.7% | +740 bps | +30 bps |
| India Revenue | ₹1,385 Cr | ₹1,013 Cr | +36.8% | – |
| International Revenue | ₹936 Cr | ₹669 Cr | +39.9% | – |
🔹 Operational Highlights
New Store Additions: 195 net new stores in Q3 (169 India, 26 International)
FY26 Store Guidance: On track to add 420 stores for the full fiscal year
Same-Store Sales Growth (SSSG) : 28% in India
Same-Pincode Sales Growth (SPSG) : 36% (800 bps premium over SSSG, indicating non-cannibalising densification)
Eye Tests Conducted: 6.3 million (+54% YoY); 49% were first-time exams – expanding total addressable market
Volume Growth: ~30% YoY
Average Transaction Size (ATS) : +7% (driven by premiumisation and loyalty)
🧠 Management Commentary: “The Compounding Has Begun”
On the post-earnings call, Peyush Bansal, Founder & CEO, struck a confident chord, signalling a structural shift in the company’s financial trajectory:
*“In Q2, we said we are entering a compounding phase. Q3 validates that decisively. This is not cost-cutting. This is structural operating leverage. The compounding has begun.”*
Bansal emphasized that Lenskart is not just gaining market share, but expanding the total addressable market (TAM) itself—evidenced by nearly half of all eye tests being conducted on first-time consumers .
🏦 Brokerage Action: Target Price Hikes, Upgrades, and Cautious Optimism
The Street has responded with aggressive target price revisions. Of the 12 analysts tracking the stock, 9 have a ‘Buy’ rating, 2 have ‘Hold’, and only 1 has ‘Sell’ .
| Brokerage | Rating | Target Price (₹) | Previous TP (₹) | Key Rationale |
|---|---|---|---|---|
| Jefferies | Buy | 575 | 520 | “Exceptional quarter”; management clarity on long-term growth; margin expansion across geographies |
| Morgan Stanley | Overweight (Upgraded) | 561 | 445 | “Massive beat”; multiple levers in place; raises growth bar |
| Macquarie | Outperform | 550 | 530 | EBITDA beat; store additions; mix-led realisation; EPS estimates raised 2-4% |
| Emkay Global | Buy | 550 | 525 | Operating leverage kicking in; strong balance sheet (~₹4,000 Cr cash); internal accruals funding expansion |
| Citi | Neutral | 520 | 500 | Execution strong, but valuations already price in growth; wants to monitor Q4 momentum |
Consensus 12-Month Target Price (Bloomberg): ₹529.83 (Upside potential: ~13.3% from current levels) .
📊 Lenskart Stock: Technical & Fundamental Snapshot (Feb 2026)
Valuation Context: Lenskart trades at a significant premium to most consumer discretionary peers. Citi’s ‘Neutral’ stance explicitly flags that “current valuations already price in growth & margin improvement trajectory” . However, bullish brokerages argue that structural operating leverage and TAM expansion justify the multiple .
🏭 IPO & Listing History: From Muted Debut to Record High
Lenskart made its public market debut on November 10, 2025, raising ₹7,278 crore via its IPO .
IPO Price Band: ₹402 per share
Listing Price: ₹390 on BSE (3% discount)
Post-Listing Low: ₹355.70
Time to All-Time High: ~3 months
Utilisation of IPO Proceeds:
Total raised via fresh issue: ₹2,080.62 crore
Utilised as of Dec 31, 2025: ₹50 crore
Balance: Parked in fixed deposits; to be deployed per stated objectives .
The offer for sale (OFS) saw partial exits by marquee investors including SoftBank (SVF II Lightbulb), Schroders, Kedaara Capital, and Alpha Wave Ventures .
🌍 International Expansion & Strategic Acquisitions
Lenskart’s Q3 performance was bolstered by strong international growth and strategic M&A:
🔹 International Segment Performance
Revenue: ₹935.9 crore (+39.9% YoY)
EBIT: ₹32.5 crore (vs ₹42.4 crore loss in Q3 FY25)
🔹 Key Acquisitions (9M FY26)
These acquisitions signal Lenskart’s intent to strengthen its technology backbone (QuantDuo, Dimension NXG) and expand global footprint (Stellio Ventures in Europe).
📅 What’s Next? Key Triggers for Lenskart Share Price in 2026
Q4 FY26 Results (May 2026): Citi has flagged this as a crucial monitorable to confirm growth sustainability post-GST disruption normalization .
Store Expansion Runway: On track to add 420 stores in FY26; progress on international rollouts .
Cash Deployment: With ~₹4,000 crore in cash (IPO proceeds + internal accruals), M&A or capacity expansion could be next .
Valuation Support vs Growth: The key debate for 2026—can Lenskart grow into its valuation?
Index Inclusion: Potential for inclusion in broader indices, triggering passive fund flows.
🧾 Expert Take: Should You Buy, Hold, or Sell?
✅ Bull Case
Structural operating leverage: Incremental revenue flowing to bottom line .
TAM expansion: Nearly 50% of eye tests are first-time consumers; Lenskart is growing the category, not just capturing share.
International turnaround: From loss to profit in one year.
Strong balance sheet: Zero debt stress; cash-rich for future growth.
⚠️ Bear Case / Cautious View
Valuation concern: P/E of ~253x implies perfection priced in; any growth deceleration could trigger de-rating .
Competition: Unorganised sector still large; organised peers (Titan Eyeplus, Warby Parker) may intensify pricing pressure.
Q4 seasonality: Historically weaker quarter; post-holiday demand dip could test momentum.
📌 Conclusion: Lenskart’s Compounding Story Gains Credibility
The Lenskart share price of ₹526.35 in February 2026 is not just a number—it is a validation of a thesis. From a loss-making startup to a ₹88,000 crore listed giant, Lenskart has demonstrated that omnichannel retail, when executed with scale and technology, delivers premium profitability.
Founder Peyush Bansal’s “compounding” narrative is no longer aspirational—it is visible in the numbers. However, with great performance comes great valuation. The stock’s trajectory in the remainder of 2026 will depend on sustained 30%+ growth and margin expansion that justifies its premium multiple.
For now, Lenskart sits at an all-time high, and the market is betting the view from the top is just the beginning.
0 Comments